Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

RBC Capital Mkts has recently initiated Cytokinetics, Inc. (CYTK) stock to Outperform rating, as announced on November 8, 2024, according to Finviz. Earlier, on August 13, 2024, Goldman had reduced ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

After hours: January 17 at 6:11:16 PM EST ...

Aficamten is under clinical development by Cytokinetics and currently in Pre-Registration for Hypertrophic Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Hypertrophic ...

Kina Bank is committed to giving back to the communities we operate in. Our commitment to giving back stems from our core values of Serve and Together, as we believe that by working and serving ...